Overexpression of hypoxia-inducible factor 1α indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radical radiotherapy for cervical cancer

Clinical Cancer Research

Volumn 9, Issue 6, 2003, Pages 2234-2240

  Bachtiary, Barbara ^a   Schindl, Monika ^a   Pötter, Richard ^a   Dreier, Bettina ^a   Knocke, Thomas Hendrik ^a   Hainfellner, Johannes A ^b   Horvat, Reinhard ^a   Birner, Peter ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; UNCLASSIFIED DRUG; VIRUS ONCOPROTEIN E6; VIRUS PROTEIN;

ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; DISEASE COURSE; DISEASE MARKER; FEMALE; GENE OVEREXPRESSION; HUMAN; HYPOXIA; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MOLECULAR CLONING; MULTIVARIATE ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REGRESSION ANALYSIS; STATISTICAL ANALYSIS; SURVIVAL; UTERINE CERVIX CANCER; WART VIRUS;

BIOLOGICAL MARKERS; CELL HYPOXIA; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROGNOSIS; SURVIVAL RATE; TRANSCRIPTION FACTORS; UTERINE CERVICAL NEOPLASMS;

EID: 0037500967     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Folkman, J. Tumor angiogenesis. Adv. Cancer Res., 43: 175-203, 1985.
2. Hockel, M., and Vaupel, P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J. Natl. Cancer Inst. (Bethesda), 93: 266-276, 2001.
3. Hall, E. J. Radiobiology for the radiologist. Philadelphia, PA: Lippincott, Williams & Wilkins, 2000.
4. Hockel, M., Schlenger, K., Aral, B., Mitze, M., Schaffer, U., and Vaupel, P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res., 56: 4509-4515, 1996.
5. Knocke, T. H., Weitmann, H. D., Feldmann, H. J., Selzer, E., and Potter, R. Intratumoral pO2-measurements as predictive assay in the treatment of carcinoma of the uterine cervix. Radiother. Oncol., 55: 99-104, 1999.
6. Sundfor, K., Lyng, H., Trope, C. G., and Rofstad, E. K. Treatment outcome in advanced squamous cell carcinoma of the uterine cervix: relationships to pretreatment tumor oxygenation and vascularization. Radiother. Oncol., 54: 101-107, 2000.
7. Fyles, A., Milosevic, M., Hedley, D., Pintilie, M., Levin, W., Manchul, L., and Hill, R. P. Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. J. Clin. Oncol., 20: 680-687, 2002.
8. Semenza, G. L. Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu. Rev. Cell Dev. Biol., 15: 551-578, 1999.
9. Jiang, B. H., Semenza, G. L., Bauer, C., and Marti, H. H. Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension. Am. J. Physiol., 271: C1172-C1180, 1996.
10. Birner, P., Schindl, M., Obermair, A., Plank, C., Breitenecker, G., and Oberhuber, G. Overexpression of hypoxia-inducible factor 1α is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res., 60: 4693-4696, 2000.
11. Aebersold, D. M., Burri, P., Beer, K. T., Laissue, J., Djonov, V., Greiner, R. H., and Semenza, G. L. Expression of hypoxia-inducible factor-1α: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res., 61: 2911-2916, 2001.
12. Koukourakis, M. I., Giatromanolaki, A., Sivridis, E., Simopoulos, C., Turley, H., Talks, K., Gatter, K. C., and Harris, A. L. Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys., 53: 1192-1202, 2002.
13. Koukourakis, M. I., Giatromanolaki, A., Skarlatos, J., Corti, L., Blandamura, S., Piazza, M., Gatter, K. C., and Harris, A. L. Hypoxia-inducible factor (HIF-1a and HIF-2a) expression in early esophageal cancer and response to photodynamic therapy and radiotherapy. Cancer Res., 61: 1830-1832, 2001.
14. Hui, E. P., Chan, A. T., Pezzella, F., Turley, H., To, K. F., Poon, T. C., Zee, B., Mo, F., Teo, P. M., Huang, D. P., Gatter, K. C., Johnson, P. J., and Harris, A. L. Coexpression of hypoxia-inducible factors 1α and 2α, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clin. Cancer Res., 8: 2595-2604, 2002.
15. Vaupel, P., Kelleher, D. K., and Hockel, M. Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Semin. Oncol., 28: 29-35, 2001.
16. Walboomers, J. M., Jacobs, M. V., Manos, M. M., Bosch, F. X., Kummer, J. A., Shah, K. V., Snijders, P. J., Peto, J., Meijer, C. J., and Munoz, N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol., 189: 12-19, 1999.
17. Ravi, R., Mookerjee, B., Bhujwalla, Z. M., Sutter, C. H., Artemov, D., Zeng, Q., Dillehay, L. E., Madan, A., Semenza, G. L., and Bedi, A. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α. Genes Dev., 14: 34-44, 2000.
18. Blagosklonny, M. V., An, W. G., Romanova, L. Y., Trepel., J., Fojo, T., and Neckers, L. P53 inhibits hypoxia-inducible factor-stimulated transcription. J. Biol. Chem., 273: 11995-11998, 1998.
19. Potter, R., Knocke, T. H., Fellner, C., Baldass, M., Reinthaller, A., and Kucera, H. Definitive radiotherapy based on HDR brachytherapy with iridium 192 in uterine cervix carcinoma: report on the Vienna University Hospital findings (1993-1997) compared to the preceding period in the context of ICRU 38 recommendations. Cancer Radiother., 4: 159-172, 2000.
20. Birner, P., Piribauer, M., Fischer, I., Gatterbauer, B., Marosi, C., Ambros, P. F., Ambros, I. M., Bredel, M., Oberhuber, G., Rössler, K., Budka, H., Harris, A. L., and Hainfellner, J. A. Vascular patterns in glioblastoma influence clinical outcome and associate with variable expression of angiogenic proteins: evidence for distinct angiogenic subtypes. Brain Pathol., 13: 133-143, 2003.
21. Xu, L., and Fidler, I. J. Acidic pH-induced elevation in interleukin 8 expression by human ovarian carcinoma cells. Cancer Res., 60: 4610-4616, 2000.
22. Birner, P., Schindl, M., Obermair, A., Breitenecker, G., and Oberhuber, G. Expression of hypoxia-inducible factor 1α in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin. Cancer Res., 7: 1661-1668, 2001.
23. Schindl, M., Bachtiary, B., Dreier, B., Birner, P., Latinovic, L., Karner, B., Breitenecker, G., and Oberhuber, G. Impact of human papillomavirus infection on the expression of the KAI1 metastasis suppressor protein in invasive cervical cancer. Cancer Lett., 62: 261-266, 2001.
24. Bachtiary, B., Obermair, A., Dreier, B., Birner, P., Breitenecker, G., Knocke, T. H., Selzer, E., and Potter, R. Impact of multiple HPV infection on response to treatment and survival in patients receiving radical radiotherapy for cervical cancer. Int. J. Cancer, 102: 237-243, 2002.
25. Saiki, R. K., Gelfand, D. H., Stoffel, S., Scharf, S. J., Higuchi, R., Horn, G. T., Mullis, K. B., and Erlich, H. A. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science (Wash. DC), 239: 487-491, 1988.
26. de Roda Husman, A. M., Walboomers, J. M., van den Brule, A. J., Meijer, C. J., and Snijders, P. J. The use of general primers GP5 and GP6 elongated at their 3′ ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J. Gen. Virol., 76: 1057-1062, 1995.
27. Karlsen, F., Kalantari, M., Jenkins, A., Pettersen, E., Kristensen, G., Holm, R., Johansson, B., and Hagmar, B. Use of multiple PCR primer sets for optimal detection of human papillomavirus. J. Clin. Microbiol., 34: 2095-2100, 1996.
28. Birner, P., Bachtiary, B., Dreier, B., Schindl, M., Joura, E. A., Breitenecker, G., and Oberhuber, G. Signal-amplified colorimetric in situ hybridization for assessment of human papillomavirus infection in cervical lesions. Mod. Pathol., 14: 702-709, 2001.
29. Haugland, H. K., Vukovic, V., Pintilie, M., Fyles, A. W., Milosevic, M., Hill, R. P., and Hedley, D. W. Expression of hypoxia-inducible factor-1α in cervical carcinomas: correlation with tumor oxygenation. Int. J. Radiat. Oncol. Biol. Phys., 53: 854-861, 2002.
30. Semenza, G. L. Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Crit. Rev. Biochem., 35: 71-103, 2000.
31. Hockel, M., and Vaupel, P. Biological consequences of tumor hypoxia. Semin. Oncol., 28: 36-41, 2001.
32. Wouters, B. G., and Brown, J. M. Cells at intermediate oxygen levels can be more important than the "hypoxic fraction" in determining tumor response to fractionated radiotherapy. Radiat. Res., 147: 541-550, 1997.
33. Semenza, G. L. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J. Appl. Physiol., 88: 1474-1480, 2000.
34. Vukovic, V., Haugland, H. K., Nicklee, T., Morrison, A. J., and Hedley, D. W. Hypoxia-inducible factor-1α is an intrinsic marker for hypoxia in cervical cancer xenografts. Cancer Res., 61: 7394-7398, 2001.
35. Lal, A., Peters, H., St. Croix, B., Haroon, Z. A., Dewhirst, M. W., Strausberg, R. L., Kaanders, J. H., van der Kogel, A. J., and Riggins, G. J. Transcriptional response to hypoxia in human tumors. J. Natl. Cancer Inst. (Bethesda), 93: 1337-2343, 2001.
36. Koong, A. C., Denko, N. C., Hudson, K. M., Schindler, C., Swiersz, L., Koch, C., Evans, S., Ibrahim, H., Le, Q. T., Terris, D. J., and Giaccia, A. J. Candidate genes for the hypoxic tumor phenotype. Cancer Res., 60: 883-887, 2000.
37. Wykoff, C. C., Pugh, C. W., Maxwell, P. H., Harris, A. L., and Ratcliffe, P. J. Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling. Oncogene, 19: 6297-6305, 2000.
38. Suzuki, H., Tomida, A., and Tsuruo, T. Dephosphorylated hypoxia-inducible factor 1α as a mediator of p53-dependent apoptosis during hypoxia. Oncogene, 20: 5779-5788, 2001.
39. An, W. G., Kanekal, M., Simon, M. C., Maltepe, E., Blagosklonny, M. V., and Neckers, L. M. Stabilization of wild-type p53 by hypoxia-inducible factor 1α. Nature (Lond.), 392: 405-408, 1998.
40. Graeber, T. G., Osmanian, C., Jacks, T., Housman, D. E., Koch, C. J., Lowe, S. W., and Giaccia, A. J. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature (Lond.), 379: 88-91, 1996.
41. Scheffner, M., Huibregtse, J. M., Vierstra, R. D., and Howley, P. M. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell, 75: 495-505, 1993.
42. Thomas, M., Pim, D., and Banks, L. The role of the E6-p53 interaction in the molecular pathogenesis of HPV. Oncogene, 18: 7690-7700, 1999.
43. Havre, P. A., Yuan, J., Hedrick, L., Cho, K. R., and Glazer, P. M. p53 inactivation by HPV16 E6 results in increased mutagenesis in human cells. Cancer Res., 55: 4420-4424, 1995.
44. Lechner, M. S., and Laimins, L. A. Inhibition of p53 DNA binding by human papillomavirus E6 proteins. J. Virol., 68: 4262-4273, 1994.
45. Kim, C. Y., Tsai, M. H., Osmanian, C., Graeber, T. G., Lee, J. E., Giffard, R. G., DiPaolo, J. A., Peehl, D. M., and Giaccia, A. J. Selection of human cervical epithelial cells that possess reduced apoptotic potential to low-oxygen conditions. Cancer Res., 57: 4200-4204, 1997.